• FDA granted Fast Track designation to Perspective Therapeutics’ investigational [212Pb]PSV359 for FAP-positive solitary fibrous tumors.
• Designation covers adults with locally advanced unresectable or metastatic disease, a rare cancer with limited treatment options.
• [212Pb]PSV359 is in a Phase 1/2a study in advanced FAP-positive solid tumors to support dose selection for Phase 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080616PRIMZONEFULLFEED9842019) on October 08, 2026, and is solely responsible for the information contained therein.